US Federal House Bill HB3082

US Federal 2025-2026 Regular Session

• Introduced: 4/29/25
• Refer: 4/29/25

Caption

Evidence-Based Drug Policy Act of 2025

Impact

The repeal of section 704(b)(12) is significant because it removes language that may have prioritized certain types of drug control measures that are not supported by current evidence or research. This change could potentially open the door for new policies that align with evolving understandings of addiction and drug use, which emphasize treatment and harm reduction over punitive measures. This shift could lead to an overhaul in how drug-related issues are approached at both the federal and state levels, promoting solutions that are informed by data rather than outdated methodologies.

Summary

House Bill 3082, titled the 'Evidence-Based Drug Policy Act of 2025', aims to repeal section 704(b)(12) of the Office of National Drug Control Policy Reauthorization Act of 1998. The primary goal of this bill is to modify existing drug policy frameworks in favor of new evidence-based approaches that reflect current research and best practices in drug treatment and prevention. By taking this action, the proponents of the bill advocate for a shift towards more effective and scientifically-backed methods for addressing drug-related issues in the United States.

Contention

However, the introduction of HB 3082 may spark debates among lawmakers and stakeholders in the drug policy arena. Opponents of the bill may express concerns about the implications of repealing longstanding sections of drug policy legislation, fearing it could lead to a lack of clear guidance in addressing drug issues or a potential increase in drug use. Supporters, on the other hand, argue that continuing outdated practices serves no one and that it is essential to prioritize approaches that reduce harm and focus on public health rather than criminalization. As discussions progress, the bill may face scrutiny and amendments as it moves through the legislative process.